Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.630 -0.010 (-0.38%)
Streaming Delayed Price Updated: 2:22 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks Gaining Momentum
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power. 
Via MarketBeat
News headline image
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.